The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.

A prokaryote was genetically engineered to develop operationally simple, high-yield biosynthetic route for the production of farnesylated proteins. The recombinant organism was modified to express a target protein, a peptide sequence fused to the target protein at a C-terminus, and an alpha and a beta subunit of a prenyltrasferase. The prenyltrasferase may be farnesyltransferase or geranylgeranyl transferase, and the peptide sequence may comprise cysteine, two hydrophobic amino acids, and an amino acid having selectivity to farnesyltransferase or geranylgeranyl transferase.